Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Gynecologic 1Gastrointestinal 1

Conditions

Uterine Cervical Neoplasms 1Rectal Neoplasms 1Oropharyngeal Neoplasms 1Anus Neoplasms 1

Interventions

Specimen Handling 116Magnetic Resonance Spectroscopy 94Biopsy 60pembrolizumab 58Carboplatin 57Cisplatin 51Nivolumab 47Cyclophosphamide 40Radiotherapy 39Paclitaxel 37Gemcitabine 34Dexamethasone 34Bevacizumab 31Radiation 30atezolizumab 29Pemetrexed 28venetoclax 25olaparib 25Etoposide 25X-Rays 24Prednisone 23Immunoglobulin G 23Doxorubicin 23Disulfides 23Vincristine 22Lenalidomide 22Leucovorin 21Ipilimumab 21durvalumab 20Taxes 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Epinephrine × 30 days × Clear all
NCT04432597 2026-05-18

HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associated Cancers

National Institutes of Health Clinical Center (CC)

Phase 1/2 Active not recruiting
39 enrolled
GastrointestinalGynecologicHead & Neck

Anus Neoplasms, Uterine Cervical Neoplasms, Oropharyngeal Neoplasms, Rectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡